Keyphrases
Glioblastoma
97%
Bevacizumab
53%
Overall Survival
37%
Recurrent Glioblastoma
32%
Irinotecan
26%
Glioblastoma multiforme
22%
Human Glioblastoma
19%
Angiotensinogen
18%
Prognostic Model
17%
Treatment Response
17%
Bevacizumab Treatment
16%
Combination Therapy
16%
Glioblastoma Cells
15%
Newly Diagnosed Glioblastoma
15%
Single Institution
13%
Prognostic Factors
13%
Patient Selection
13%
Glioma Patients
13%
Orthotopic Model
13%
Progression-free Survival
12%
Bevacizumab Therapy
10%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
10%
Promoter Methylation
9%
Gliosarcoma
9%
Methylation Status
9%
Prognostic Biomarker
9%
MicroPET
9%
Non-responders
9%
Predictive Biomarker
9%
Quality of Life
9%
Multivariate Analysis
9%
Surgical Resection
9%
Tumor
9%
Temozolomide
9%
Xenograft
9%
Methylation
9%
Clinical Characteristics
8%
Clinical Variables
8%
DNA Methylation (DNAm)
8%
Performance Status
8%
Gene Expression
8%
Tumor Tissue
7%
Cell Viability
7%
MRNA Level
7%
18F-fluoroethyl-L-tyrosine (18F-FET)
7%
Stem Cells
7%
Intracranial Metastases
7%
Cell Survival
7%
Glioma
6%
Cancer Cells
6%
Medicine and Dentistry
Glioblastoma
100%
Neoplasm
28%
Bevacizumab
26%
Overall Survival
24%
Ganglioglioma
20%
Biological Marker
19%
Irinotecan
19%
Vasculotropin
15%
Xenograft
14%
Fluorine-18
13%
Treatment Response
11%
Progression Free Survival
10%
Surgery
10%
Gliosarcoma
9%
Temozolomide
8%
Positron Emission Tomography
8%
In Vitro
8%
Cell Survival
7%
Positron Emission Tomography
7%
Metastatic Carcinoma
6%
Hypoxia
6%
Histone Demethylase
6%
Vasculotropin C
6%
Cell-Free DNA
6%
Lysine
6%
Drug Resistance
6%
Urokinase Receptor
6%
Vasculotropin Receptor 2
6%
Quality of Life
6%
Pleiotrophin
6%
Cell Viability
6%
Placental Growth Factor
6%
Endothelial Cell Sprouting
6%
Notch
6%
Stem Cell
6%
Epidermal Growth Factor Receptor
6%
Tumor Recurrence
6%
Ob/Ob Mouse
6%
Proteomics
6%
Insulin Dependent Diabetes Mellitus
6%
Immune Cell Infiltration
6%
Radiation Therapy
5%
Multivariate Analysis
5%
Protein P53
5%
Malignant Neoplasm
5%
Chromosomal Instability
5%
Magnetic Resonance Imaging
5%
